DailyIQ
|
Last updated1 minute ago

GKOS·Glaukos Corporation

$181.28
-4.37 (-2.35%)
High
$187.25
Open
$186.21
Market Cap
11.05B
52W High
$191.62
Low
$181.00
P. Close
$181.28
P/E
-
52W Low
$73.16
Fwd P/E
366.61
DailyIQ Est.
$202.58
Inst. Ownership
-
Short Interest
5.97%
Technical Score (1D)
82
BUY
News Sentiment
70
BULLISH
BTIG’s latest research notes a bullish upgrade for Glaukos, raising its price target from $193 to $202 and citing recent clinical milestones in the company’s ocular therapeutic pipeline. The higher target signals confidence that the company’s products will gain regulatory traction and drive revenue growth over the next 1–10 trading days, so investors should watch the upcoming earnings release for confirmation of sales momentum. Glaukos will also be a featured speaker at the upcoming Wells Fargo Healthcare Conference, where it plans to showcase its latest ocular advances and engage with industry stakeholders; the event offers a chance to gauge peer and investor sentiment, though it is unlikely to move the stock immediately. The conference could also reveal potential collaboration or partnership opportunities that might accelerate product commercialization. An insider sale of $3.6 million in GKOS shares was reported in an SEC filing, a short‑term liquidity move that does not necessarily indicate a bearish view but warrants monitoring for future insider activity that could influence short‑term volatility. The combination of a higher price target, a high‑profile conference appearance, and a sizable insider sale creates a mixed outlook: the pipeline progress supports a positive trajectory, while the insider sale introduces some short‑term uncertainty. For the next trading week, watch the earnings call for sales data and any updates on regulatory approvals, and keep an eye on post‑conference investor reactions that could signal a shift in market perception.

EPS

EstBeatMiss
$-0.29$-0.23$-0.18$-0.12$-0.06Q3'25Q3'26
QtrEstActual+/−
Q3'26$-0.09 - -
Q3'25$-0.26$-0.16+38.9%

Revenue

EstBeatMiss
$128M$140M$152M$164M$177MQ3'25Q3'26
QtrEstActual+/−
Q3'26$171M - -
Q3'25 - $134M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

GKOS Stock Snapshot

GKOS is currently trading at $181.28, giving Glaukos Corporation a market cap of 11.05B. Today's range spans $181.00–$187.25, with shares opening at $186.21 and moving down $4.37 (2.4%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 70/100.

Over the past year GKOS has traded between $73.16 and $191.62 - the current price is +147.8% off the 52-week low and -5.4% from the high. 22 analysts cover the stock with a Buy consensus and a mean 12-month target of $197.15 (range $172.00–$225.00), implying upside of +8.8%.

Glaukos Corporation (GKOS) is a large-cap in the broader market with 11.05B in market cap, and the current setup is one of the cleaner bullish reads in the space. Technical score: 82/100 (BUY). Sentiment: bullish at 70/100. Price: $181.28 (near 52-week highs). The 52-week range of $73.16–$191.62 provides structural context - and the current technical/sentiment alignment is the type of setup that attracts both momentum and growth-oriented capital.

Earnings revision cycles in large-cap the broader market names tend to compound: when technicals confirm a BUY thesis (82/100) and news sentiment (70/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $181.28 (near 52-week highs), GKOS's position within the $73.16–$191.62 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.